Hepatic Disease in HIV-Infected Patients

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 9/4/18 (What's New)

Summary

  • Studies of hydroxymethylglutaryl-CoA reductase inhibitors (statins) have reported some evidence of reductions in serum ALT[Gómez-Domínguez 2006; Hatzitolios 2004; Athyros 2006; Abel 2009]
  • The US National Lipid Association Statin Liver Safety Task Force has concluded that statin therapy is safe in patients with NAFLD and dyslipidemia[Bays 2014]
  • The AASLD and EASL guidelines recommend the use of statins for treatment of dyslipidemia in patients with NAFLD and NASH[AASLD NAFLD; EASL NAFLD]

Action required